Aeglea BioTherapeutics, Inc.
https://www.aegleabio.com/Overview
Investors 3
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| RA Capital Management | racap.com | |
| OrbiMed | orbimed.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Mar 23, 2015 | Series B round | $44M |
Mentions in press and media 11
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 6, 2021 | Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency | |
| Dec 1, 2020 | Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria | |
| Nov 24, 2020 | Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference | |
| Feb 6, 2019 | Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering | |
| Jun 29, 2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| Apr 8, 2016 | Austin-based Aeglea BioTherapeutics Goes Public and Raises $50 Million | Aeglea BioTherapeutics went public on the NASDAQ Stock Market Thursday at $10 a share with an Initial Public Offering bringing in $50 million. |
| Aug 5, 2015 | Ten Life Sciences Companies to Watch in Central Texas | |
| Mar 27, 2015 | Funding roundup - week ending 3/27/15 | Accel Partners, Falcon Social, Augmented Pixels, Socratic, iAngels, Realm, Hedvig, ZipMatch, Skycure (Come mingle with hundreds of top venture capitalists representing $10B-plus in capital under management, including Khosla Ventures, Greylo... |
| Mar 23, 2015 | Aeglea Biotherapeutics Raises $44M in Series B Funding | Aeglea Biotherapeutics , an Austin, Texas-based biopharmaceutical company focused on treating tumor metabolism, raised $44m in Series B funding. The round was led by existing backers Lilly Ventures and Novartis Venture Fund with participati... |
Reviews 0
FAQ about Aeglea BioTherapeutics, Inc.
How much funding has Aeglea BioTherapeutics, Inc. raised?
Aeglea BioTherapeutics, Inc. has raised $94M in total across 2 funding rounds.
What funding rounds has Aeglea BioTherapeutics, Inc. raised?
Parsers VC lists 2 funding rounds of Aeglea BioTherapeutics, Inc., among them a Series B round of $44M on Mar 23, 2015.
Who has invested in Aeglea BioTherapeutics, Inc.?
Parsers VC lists 3 investors of Aeglea BioTherapeutics, Inc., among them RA Capital Management and OrbiMed.
What has the press written about Aeglea BioTherapeutics, Inc.?
Parsers VC has collected 11 articles mentioning Aeglea BioTherapeutics, Inc., among them “Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency” (May 6, 2021) and “Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria” (Dec 1, 2020).
Is Aeglea BioTherapeutics, Inc. still active?
Yes, Aeglea BioTherapeutics, Inc. is active; its latest activity on Parsers VC dates from Aug 5, 2021.